1. Home
  2. ZKH vs VNDA Comparison

ZKH vs VNDA Comparison

Compare ZKH & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZKH

ZKH Group Limited

HOLD

Current Price

$3.11

Market Cap

571.2M

Sector

N/A

ML Signal

HOLD

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

HOLD

Current Price

$7.03

Market Cap

474.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZKH
VNDA
Founded
1998
2002
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
571.2M
474.0M
IPO Year
2022
2005

Fundamental Metrics

Financial Performance
Metric
ZKH
VNDA
Price
$3.11
$7.03
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.90
AVG Volume (30 Days)
36.4K
3.8M
Earning Date
03-19-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$216,105,000.00
Revenue This Year
$2.58
$21.35
Revenue Next Year
$10.62
$37.40
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.72
52 Week Low
$2.20
$3.81
52 Week High
$3.90
$9.91

Technical Indicators

Market Signals
Indicator
ZKH
VNDA
Relative Strength Index (RSI) 45.59 38.72
Support Level $2.82 $4.36
Resistance Level $3.14 $8.29
Average True Range (ATR) 0.20 0.58
MACD -0.05 -0.21
Stochastic Oscillator 69.84 8.17

Price Performance

Historical Comparison
ZKH
VNDA

About ZKH ZKH Group Limited

ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: